Literature DB >> 10219446

Surgery during chemotherapy and at relapse of ovarian cancer.

J S Berek1, C Tropé, I Vergote.   

Abstract

During chemotherapy and after relapse several types of operations are used in ovarian cancer: secondary cytoreductive surgery, interval cytoreductive surgery, second-look surgery, and palliative secondary surgery. The role of these operations has been difficult to define because there is considerable variation in the patterns of behaviour of tumours among those with persistent or recurrent disease. The definitions, indications and impact of these procedures are reviewed.

Entities:  

Mesh：

Year:  1999        PMID： 10219446     DOI： 10.1023/a:1008338830718

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  4 in total

1.  Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

Authors:  Ahmet Bilici; Bala Basak Oven Ustaalioglu; Mesut Seker; Nesrin Canpolat; Bulent Tekinsoy; Taflan Salepci; Mahmut Gumus
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

2.  The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review.

Authors:  N B Rettenmaier; C R Rettenmaier; T Wojciechowski; L N Abaid; J V Brown; J P Micha; B H Goldstein
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

3.  Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.

Authors:  Miriam Lenhard; Alexandra Tsvilina; Lan Schumacher; Markus Kupka; Nina Ditsch; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-01-03       Impact factor: 4.430

4.  Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.

Authors:  Verena Engelstaedter; Sabine Heublein; Anamur Lan Schumacher; Miriam Lenhard; Helen Engelstaedter; Ulrich Andergassen; Margit Guenthner-Biller; Christina Kuhn; Brigitte Rack; Markus Kupka; Doris Mayr; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-12-15       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.